p21(CIP1) is dispensable for the G2 arrest caused by genistein in human melanoma cells

Experimental Cell Research

Volumn 258, Issue 1, 2000, Pages 101-108

  Casagrande, Fabrice ^a   Darbon, Jean Marie ^a  

^a CHU PURPAN   (France)

Author keywords

Cell cycle; Cyclin dependent kinase; Isoflavonoid; Melanoma cells; p21(CIP1)

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; GENISTEIN; ISOFLAVONOID; MUTANT PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN P21; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CDKN1A PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELLULAR DISTRIBUTION; CHOROID MELANOMA; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; MELANOMA CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RAT; ANIMAL; CELL CULTURE; CELL CYCLE; CELL LINE; CHOROID TUMOR; CYTOLOGY; DRUG EFFECT; EMBRYO; GENETICS; KINETICS; METABOLISM; PHYSIOLOGY; RNA PROCESSING;

ANIMALIA;

ANIMALS; CELL CYCLE; CELL LINE; CHOROID NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; EMBRYO; ENZYME INHIBITORS; FIBROBLASTS; G2 PHASE; GENISTEIN; HUMANS; KINETICS; MICE; RATS; RNA PROCESSING, POST-TRANSCRIPTIONAL; TUMOR CELLS, CULTURED;

EID: 0034631517     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.4914     Document Type: Article

References (52)

1. Peterson G. Evaluation of the biochemical targets of genistein in tumor cells. J. Nutr. 125:1995;784S-789S.
2. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:1987;5592-5595.
3. Markovits J., Linassier C., Fossé P., Couprie J., Pierre J., Jacquemin-Sablon A., Saucier J. M., Le Pecq J. B., Larsen A. K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49:1989;5111-5117.
4. Linassier C., Pierre M., Le Pecq J. B., Pierre J. Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem. Pharmacol. 39:1989;187-193.
5. Matsukawa Y., Marui N., Sakai T., Satomi Y., Yoshida M., Matsumoto K., Nishino H., Aoike A. Genistein arrests cell cycle progression at G2-M. Cancer Res. 53:1993;1328-1331.
6. Spinozzi F., Pagliacci M. C., Migliorati G., Moraca R., Grignani F., Riccardi C., Nicoletti I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 18:1994;431-439.
7. WAF1/CIP1 induction, G2/M arrest, and apoptosis. J. Cell. Biochem. 69:1998;44-54.
8. Cip1/WAF1 expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun. 251:1998;291-295.
9. Pines J. Cyclins and cyclin-dependent kinases: A biochemical view. Biochem. J. 308:1995;697-711.
10. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
11. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
12. Gu Y., Turck C. W., Morgan D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature. 366:1993;707-710.
13. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
14. Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
15. Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T., Hannon G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:1995;552-557.
16. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
17. Waldman T., Kinzler K. W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:1995;5187-5190.
18. Noda A., Ning Y., Venable S. F., Pereira-Smith O. M., Smith J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:1994;90-98.
19. WAF1/CIP1 expression in the absence of p53. Oncogene. 9:1994;3397-3406.
20. WAF-1/CIP1 during differentiation. Oncogene. 9:1994;3389-3396.
21. Guo K., Wang J., Andres V., Smith R. C., Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol. Cell. Biol. 15:1995;3823-3829.
22. Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 267:1995;1018-1021.
23. Datto M. B., Li Y., Panus J. F., Howe D. J., Xiong Y., Wang X.-F. Transforming growth factor β induces the cyclin-dependent inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA. 92:1995;5545-5549.
24. Li C.-Y., Suardet L., Little J. B. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem. 270:1995;4971-4974.
25. WAF1/Cip1 and alter cell cycle control in squamous carcinoma cells. Oncogene. 12:1996;2369-2376.
26. Jeoung D. I., Tang B., Sonenberg M. Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J. Biol. Chem. 270:1995;18367-18373.
27. Zhu X., Ohtsubo M., Bohmer R. M., Roberts J. M., Assoian R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133:1996;391-403.
28. Waf1 pathway in response to disruption of cell-matrix interactions. J. Biol. Chem. 272:1997;29091-29098.
29. Harper J. W., Elledge S. J., Keyomarsi K., Dynlacht B., Tsai L.-H., Zhang P., Dobrowolski S., Bai C., Connel-Crowley L., Swindell E., Fox M. P., Wei N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell. 6:1995;387-400.
30. Li Y., Jenkins C. W., Nichols M. A., Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 9:1994;2261-2268.
31. Cip1 at the onset of mitosis: A role at the G2/M-phase transition. Mol. Cell. Biol. 18:1998;546-557.
32. Waf1/Cip1 expression. Oncogene. 17:1998;1691-1703.
33. waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene. 16:1998;431-441.
34. Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18:1998;629-643.
35. Cayrol C., Knibiehler M., Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 16:1998;311-320.
36. Mouriaux F., Casagrande F., Pillaire M. J., Manenti S., Malecaze F., Darbon J. M. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest. Ophtalmol. Vis. Sci. 39:1998;876-884.
37. WAF1,CIP1,SDI1 mutant (Arg94 → Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J. Biol. Chem. 271:1996;15782-15786.
38. WAF1/CIP1/SDI1 protein in phorbol ester-induced G2/M arrest. J. Biol. Chem. 271:1996;29556-29560.
39. Cip1/Waf1 in UV-irradiated and transformed cells. Oncogene. 16:1998;1333-1343.
40. Zhang H., Hannon G. J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1994;1750-1758.
41. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
42. Morla A. O., Draetta G., Beach D., Wang J. Reversible tyrosine phosphorylation of cdc2: Dephosphorylation accompanies activation during entry into mitosis. Cell. 58:1989;193-203.
43. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res. 52:1992;1817-1822.
44. Darbon J. M., Penary M., Escalas N., Casagrande F., Goubin-Gramatica F., Baudouin C., Ducommun B. Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells. J. Biol. Chem. 275:2000;15363-15369.
45. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J. P., Sedivy J. M., Kinzler K. W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1998;1497-1501.
46. Polyak K., Waldman T., He T. C., Kinzler K. W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1996;1945-1952.
47. Choi Y. H., Zhang L., Lee W. H., Park K. Y. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int. J. Oncol. 13:1998;391-396.
48. CIP1 is not required for the early G2 checkpoint response to ionizing radiation. Cancer Res. 55:1995;2500-2502.
49. Waldman T., Lengauer C., Kinzler K. W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
50. Waf1/Cip1 inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol. 19:1999;205-215.
51. Traganos F., Ardelt B., Halko N., Bruno S., Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res. 52:1992;6200-6208.
52. cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res. 50:1990;3761-3766.